Smart Ocular Drug Delivery for Chronic Glaucoma Management: The Pharmaceutical Formulation Perspective

Medy Angyelile Amon, S Rajarajan, Usha.G.K, Beny Baby, K Ramesh

Glaucoma stands as a leading global cause of irreversible blindness, traditionally managed through lifelong, topical intraocular pressure (IOP)-lowering drops. However, conventional eye drops suffer from poor ocular bioavailability (<5%), driven by physiological barriers such as reflex tearing, blinking, and nasolacrimal drainage. This rapid precorneal loss necessitates frequent dosing, culminating in poor patient adherence, fluctuating IOP, and accelerated visual field loss. Objective of this review evaluates modern ophthalmic drug delivery systems, specifically focusing on thermosensitive in situ gelling systems designed to prolong precorneal retention, simplify dosing regimens, and maximize therapeutic outcomes in glaucoma management. Methods of comprehensive synthesis of glaucoma pathophysiology, aqueous humour dynamics, and conventional therapeutic constraints was performed. The review examines various stimuli-responsive polymers—categorized by temperature, pH, and ion activation triggers—highlighting the physical mechanisms governing their phase transitions. Special emphasis is placed on synthetic polyether copolymers like Poloxamer 407, analyzing their reverse thermal gelation behaviors, micellar assembly mechanisms, and compounding strategies involving secondary mucoadhesive polymers. Furthermore, modern optimization frameworks utilizing statistical Design of Experiments (DoE) and Quality by Design (QbD) principles are evaluated. Results of In situ gelling systems effectively bypass the constraints of traditional eye drops by instilling easily as a liquid and immediately setting into a solid gel upon contact with the ocular surface temperature (~32–35 °C). While solitary Poloxamer 407 vehicles exhibit poor mucoadhesion and rapid dilution under tear flow, combining them with secondary bioadhesive polymers (e.g., Carbopol, HPMC, or chitosan) strengthens the physical matrix, extends transcorneal drug release, and limits systemic absorption. The application of Box-Behnken or central composite response surface designs successfully establishes a predictable "design space" that ensures optimal gelation boundaries, critical quality attributes, and reliable verification protocols. In Conclusion the thermosensitive in situ gels serve as a robust, non-invasive, and clinically viable compromise between conventional drops and complex intraocular implants. By lowering application frequency and stabilizing long-term IOP control, these systems present an accessible strategy to enhance elderly patient adherence and reduce global blindness rates.